Literature DB >> 34258745

Covalent Antiviral Agents.

Sako Mirzaie1, Fatemeh Abdi2, Amin GhavamiNejad2, Brian Lu2, Xiao Yu Wu2.   

Abstract

Nowadays, many viral infections have emerged and are taking a huge toll on human lives globally. Meanwhile, viral resistance to current drugs has drastically increased. Hence, there is a pressing need to design potent broad-spectrum antiviral agents to treat a variety of viral infections and overcome viral resistance. Covalent inhibitors have the potential to achieve both goals owing to their biochemical efficiency, prolonged duration of action, and the capability to inhibit shallow, solvent-exposed substrate-binding domains. In this chapter, we review the structures, activities, and inhibition mechanisms of covalent inhibitors against severe acute respiratory syndrome coronavirus 2, dengue virus, enterovirus, hepatitis C virus, human immunodeficiency virus, and influenza viruses. We also discuss the application of in silico study in covalent inhibitor design.
© 2021. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Activities; Covalent antiviral agents; In silico study; Mechanisms; Structures

Year:  2021        PMID: 34258745     DOI: 10.1007/978-981-16-0267-2_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  133 in total

Review 1.  Mechanistic basis of enzyme-targeted drugs.

Authors:  James G Robertson
Journal:  Biochemistry       Date:  2005-04-19       Impact factor: 3.162

Review 2.  Covalent modifiers: an orthogonal approach to drug design.

Authors:  Michele H Potashman; Mark E Duggan
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

3.  Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values.

Authors:  Ben-Fillippo Krippendorff; Roland Neuhaus; Philip Lienau; Andreas Reichel; Wilhelm Huisinga
Journal:  J Biomol Screen       Date:  2009-08-12

Review 4.  Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.

Authors:  Renato A Bauer
Journal:  Drug Discov Today       Date:  2015-05-19       Impact factor: 7.851

Review 5.  The behavior and significance of slow-binding enzyme inhibitors.

Authors:  J F Morrison; C T Walsh
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1988

Review 6.  The Taxonomy of Covalent Inhibitors.

Authors:  Alfred Tuley; Walter Fast
Journal:  Biochemistry       Date:  2018-04-30       Impact factor: 3.162

7.  Discovery of host-targeted covalent inhibitors of dengue virus.

Authors:  Mélissanne de Wispelaere; Margot Carocci; Yanke Liang; Qingsong Liu; Eileen Sun; Michael L Vetter; Jinhua Wang; Nathanael S Gray; Priscilla L Yang
Journal:  Antiviral Res       Date:  2016-12-26       Impact factor: 5.970

8.  Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.

Authors:  David Lembo; Manuela Donalisio; Andrea Civra; Monica Argenziano; Roberta Cavalli
Journal:  Expert Opin Drug Deliv       Date:  2017-08-03       Impact factor: 6.648

9.  An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors.

Authors:  Samer I Al-Gharabli; Syed T Ali Shah; Steffen Weik; Marco F Schmidt; Jeroen R Mesters; Daniel Kuhn; Gerhard Klebe; Rolf Hilgenfeld; Jörg Rademann
Journal:  Chembiochem       Date:  2006-07       Impact factor: 3.164

Review 10.  Covalent inhibitors: a rational approach to drug discovery.

Authors:  Fandi Sutanto; Markella Konstantinidou; Alexander Dömling
Journal:  RSC Med Chem       Date:  2020-07-02
View more
  1 in total

1.  In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.

Authors:  Luis Heriberto Vázquez-Mendoza; Humberto L Mendoza-Figueroa; Juan Benjamín García-Vázquez; José Correa-Basurto; Jazmín García-Machorro
Journal:  Int J Mol Sci       Date:  2022-04-03       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.